Serum 8-isoprostane levels in patients with resistant oral lichen planus before and after treatment with lycopene: a randomized clinical trial

Background Oral lichen planus is an autoimmune disease in which topical steroids are the first line of treatment. The adverse effects of systemic corticosteroids prescribed for resistant oral lichen planus cases advocate alternative modalities. Lycopene is an antioxidant with a wide range of benefic...

Full description

Saved in:
Bibliographic Details
Published in:BMC oral health 2021-07, Vol.21 (1), p.1-343, Article 343
Main Authors: Eita, Aliaa Abdelmoniem Bedeir, Zaki, Azza Mohamed, Mahmoud, Sabah Abdelhady
Format: Article
Language:English
Subjects:
Analysis
Antioxidants
Autoimmune diseases
Biochemistry
Care and treatment
Clinical trials
Corticosteroids
Dentistry
Diagnosis
Disease
Drug dosages
Erythema
Free radicals
Inflammation
Isoprostanes
Laboratories
Lichen planus
Lipid peroxidation
Lycopene
Measurement
Medicine
Oral lichen planus
Outpatient care facilities
Oxidative stress
Pain
Patients
Periodontics
Prednisolone
Sample size
Serum levels
Skin diseases
Steroid hormones
Testing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Oral lichen planus is an autoimmune disease in which topical steroids are the first line of treatment. The adverse effects of systemic corticosteroids prescribed for resistant oral lichen planus cases advocate alternative modalities. Lycopene is an antioxidant with a wide range of beneficial properties. This trial aimed to evaluate the effect of pure lycopene as compared to systemic corticosteroids (Prednisolone) on the symptoms, signs and oxidative stress in patients with erosive oral lichen planus recalcitrant to topical steroids. Methods Twenty patients were randomly divided into the test (lycopene) and control (corticosteroids) groups. Numeric rating scale and Escudier et al. (Br J Dermatol 4:765-770, 2007. Results There was a significant reduction in signs and symptoms after the end of treatment in each group. However, no significant difference was found between the lycopene and the corticosteroids group. Moreover, a significant reduction in 8-isoprostane levels was observed in the lycopene group from baseline and as compared to the control group. Conclusions Based on the study results, lycopene is a safe and effective therapeutic modality for resistant oral lichen planus. 8-isoprostane is a biomarker of lipid peroxidation that can be reduced by lycopene. Trial registration ID: PACTR202003484099670. 'Retrospectively registered on 11/3/2020'. Keywords: Isoprostanes, Lycopene, Oral lichen planus, Oxidative stress, Prednisolone
ISSN:1472-6831
1472-6831
DOI:10.1186/s12903-021-01711-z